Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Multiple Myeloma 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

pembrolizumab 38Bevacizumab 23Cyclophosphamide 22Standard of Care 18Blood Specimen Collection 17Carboplatin 16Paclitaxel 15Nivolumab 14Gemcitabine 14Pemetrexed 13Exercise 13Cisplatin 12atezolizumab 11Radiotherapy 11Fluorouracil 11Doxorubicin 11Surveys and Questionnaires 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Cetuximab 9Biopsy 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Docetaxel 8olaparib 7Temozolomide 7Prednisone 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Trail Making Test × 90 days × Clear all
NCT06417190 2026-05-04

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Cedars-Sinai Medical Center

Phase 2 Recruiting
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡